Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review.
Natalia A DiazJuan AmbrosioniMontserrat TusetMercé BrunetFrederic CofanGonzalo CrespoPablo RuizMaria Dolores Redondo PachonMarta CrespoMónica Marín-CasinoAsunción MorenoJosé M Mirónull nullPublished in: Infectious diseases and therapy (2021)
People living with HIV should be considered candidates for solid-organ transplantation (SOT). However, managing HIV-infected patients undergoing SOT represents a major challenge due to the potential drug-drug interactions between antiretroviral drugs and immunosuppressive agents, particularly when resorting to antiretroviral drugs that require pharmacokinetic enhancers. We report three cases of cobicistat-tacrolimus co-administration, two of which also include the co-administration of mTOR inhibitors, in HIV-positive patients undergoing SOT (2 kidney and 1 liver recipient). We review previously reported cases and provide recommendations for initial management following transplantation.
Keyphrases
- hiv infected
- antiretroviral therapy
- hiv positive
- patients undergoing
- human immunodeficiency virus
- hiv infected patients
- hiv aids
- men who have sex with men
- south africa
- cell proliferation
- stem cells
- adverse drug
- risk assessment
- emergency department
- mesenchymal stem cells
- human health
- clinical practice
- kidney transplantation